SBIR/STTR Research Award

A Novel & Tailorable Topical Wound Therapy Based on a Semi-Interpenetrating Polym

Award identifier d300ccd7505ec25f696c3fda0e4b938e5e9151927427a9ad35aa059e696b8ad2Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$141,323

Program and phase

SBIR · Phase I

Award year

2007

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Iasis Molecular Sciences INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
P8KSLPQ236L5
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Abstract A water-soluble, inexpensive, and biocompatible polymer with unique properties and processing characteristics has been proven effective against multiple serine and metalloproteases in testing. The polymer is used to formulate wound therapies that offer an alternative to existing costly products. The major specific aim(s) of this work detail the formulation and animal evaluation of a hydrogel dressing that releases the water-soluble polymer agent in order to control the proteolytic environment of a chronic wound as well as deliver a secondary agent such as an anti-oxidant. This simple and rational therapy is based upon the idea that controlling proteolysis in a chronic wound environment could result in a more favorable healing environment. The polymer technology described herein may have application beyond wound therapies where controlling proteases and delivering a secondary agent simultaneously may be beneficial. Conservative estimates suggest that over 2 million people annually in the U.S. suffer from chronic ulcers (Rees et. al., 1999) and these numbers are expected to increase in view of the aging population and the rise of diabetes. The prevalence of diabetes for all age-groups worldwide has been estimated to be 2.8% in 2000 and will rise to 4.4% in 2030. Accordingly, the total number of people with diabetes is projected to approach 366 million in 2030. Among persons diagnosed as having diabetes mellitus, the prevalence of foot ulcers is 4% to 10%, the annual population-based incidence is 1.0% to 4.1%, and the lifetime incidence may be as high as 25%. In addition, the incidence of ulcer recurrence after complete healing approaches 30% within 12 months. Diabetic foot ulcers cause substantial emotional, physical, productivity, and financial losses. The estimated cost of treating a diabetic foot ulcer in 1999 was $18,000. In instances requiring amputation, these costs jumped to $28 000. These estimates do not take into account the personal and socioeconomic impact of these wounds on a patient's life. A wound treatment that utilizes a commercially available & inexpensive, water- soluble polymer of tailorable utility that leverages our fundamental understanding of the underlying biology and biochemistry of chronic wounds in order to provide a multifaceted treatment is the subject of our investigation. The water-soluble polymer will be formulated into a dressing of three derivative forms that will be evaluated for their capacities to control the levels of certain damaging wound proteases via inhibition, and affect the wound by additionally delivering an NO donor, an NO precursor, or an antioxidant to the wound site.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

8 SBIR/STTR records share this UEI (2007–2024). Reported award amounts total $2,789,689. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.